Payment overview · 2025
General Payments
$140.57
7 reported records · 5 companies
Healthcare provider profile · identity verified
Patricia E Noble, CFNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BOWLING GREEN, OH · NPI 1588605711
Verified facts
What the public records show
CMS Open Payments records show Patricia E Noble, CFNP received $140.57 in general payments during 2025 across 7 reported records.
Laborie Medical Technologies Corp. accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Laborie Medical Technologies Corp. | Unresolved — no canonical attribution shown | $44.00 | 31.3% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $30.93 | 22.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.38 | 16.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.11 | 15.7% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $20.15 | 14.3% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $140.57 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EndoSheath Technology Normalized: endosheath technology |
Device | Laborie Medical Technologies Corp. | $44.00 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $30.93 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $20.15 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $20.15 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tamsulosin Hcl | Tamsulosin Hcl | 511 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 203 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 31 |
| Finasteride | Finasteride | 187 | 49 |
| Furosemide | Furosemide | 181 | 45 |
| Gabapentin | Gabapentin | 149 | 27 |
| Dutasteride | Dutasteride | 137 | 35 |
| Eliquis | Apixaban | 117 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 108 | 12 |
| Sertraline Hcl | Sertraline Hcl | 107 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 94 | 17 |
| Tramadol Hcl | Tramadol Hcl | 93 | 16 |
| Glimepiride | Glimepiride | 83 | 13 |
| Myrbetriq | Mirabegron | 82 | 14 |
| Levofloxacin | Levofloxacin | 80 | 54 |
| Lorazepam | Lorazepam | 79 | 20 |
| Omeprazole | Omeprazole | 75 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 13 |
| Fluconazole | Fluconazole | 69 | 36 |
| Jardiance | Empagliflozin | 69 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 13 |
| Cephalexin | Cephalexin | 62 | 43 |
| Silodosin | Silodosin | 62 | 17 |
| Trospium Chloride | Trospium Chloride | 59 | 19 |
| Prednisone | Prednisone | 58 | 22 |
| Lisinopril | Lisinopril | 55 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 15 |
| Carvedilol | Carvedilol | 51 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Bumetanide | Bumetanide | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 47 | suppressed |
| Famotidine | Famotidine | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 24 |
| Simvastatin | Simvastatin | 43 | suppressed |
| Ketoconazole | Ketoconazole | 42 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 12 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 33 |
| Mirtazapine | Mirtazapine | 38 | 14 |
| Gemtesa | Vibegron | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 11 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 32 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 20 |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Admelog Solostar | Insulin Lispro | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 27 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Metolazone | Metolazone | 26 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | 11 |
| Sulfasalazine | Sulfasalazine | 23 | suppressed |
| Bicalutamide | Bicalutamide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Losartan Potassium | Losartan Potassium | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Nyamyc | Nystatin | 20 | 11 |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 15 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 19 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 13 |
| Torsemide | Torsemide | 18 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Linezolid | Linezolid | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $140.57 · 7 records | Laborie Medical Technologies Corp. | EndoSheath Technology, GRAFIX PL, Kerecis GraftGuide, Kerecis SurgiClose, ORGOVYX, XTANDI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error